Substudy 02B: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With First Line (1L) Advanced Melanoma (MK-3475-02B/KEYMAKER-U02)

NCT04305054 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

315

Enrollment

INDUSTRY

Sponsor class

Conditions

Melanoma

Interventions

BIOLOGICAL: Pembrolizumab
BIOLOGICAL: Vibostolimab
BIOLOGICAL: Pembrolizumab/Quavonlimab
DRUG: Lenvatinib
BIOLOGICAL: Favezelimab/Pembrolizumab
DRUG: ATRA

Sponsor

Merck Sharp & Dohme LLC